<DOC>
	<DOCNO>NCT00142298</DOCNO>
	<brief_summary>This trial conduct open-label , extended-term study patient chronic hepatitis B previously complete Idenix-sponsored trial telbivudine .</brief_summary>
	<brief_title>Telbivudine Adults Previously Treated Idenix-Sponsored Telbivudine Studies</brief_title>
	<detailed_description>Patients 6 feeder trial could eligible enter current study CLDT600A2303 ( NCT00142298 ) meet inclusion/exclusion criterion . The feeder study follow : - CLDT600A2302 ( NV-02B-007 ) ( NCT00057265 ) , GLOBE study , Phase III , randomize , doubleblind , multi-center , 104-week , pivotal study telbivudine vs. lamivudine treatment na誰ve patient compensate chronic hepatitis B. CLDT600A2302/NV-02B-007 ( NCT00057265 ) hereafter refer study 2302 . - NV-02B-015 ( NCT00131742 ) Phase III , randomize , double-blind , 104-week study compare efficacy safety telbivudine ( 600 mg/day ) lamivudine ( 100 mg/day ) treatment na誰ve Chinese patient compensate chronic hepatitis B. NV-02B-015 ( NCT00131742 ) hereafter refer study 015 . - CLDT600A2301 ( NV-02B-011 ) ( NCT00076336 ) Phase III , randomize double-blind , multi-center , 104-week , pivotal study telbivudine ( 600 mg/day ) vs. lamivudine ( 100 mg/day ) treatment-na誰ve adult decompensated chronic hepatitis B. CLDT600A2301/NV-02B-011 ( NCT00076336 ) hereafter refer study 2301 . - NV-02B-010 ( NCT00124241 ) Phase IIb , 104-week extension study telbivudine , lamivudine combination agent patient chronic hepatitis B complete core study NV-02B-003 ( NCT00124241 ) . NV-02B-010 ( NCT00124241 ) hereafter refer study 010 . NV-02B-003 ( NCT00124241 ) Phase IIa , 52-week study telbivudine , lamivudine combination agent patient HBeAg-positive chronic hepatitis B . - CLDT600A2401 ( NV-02B-018 ) ( NCT00115245 ) Phase IIIb , randomize , open-label , multi-center,52-week study telbivudine vs. adefovir dipivoxil 24 week switch telbivudine another 28 week treatment-na誰ve patient compensate chronic hepatitis B. CLDT600A2401/NV-02B-018 ( NCT00115245 ) hereafter refer study 2401 . - CLDT600A2402 ( NV-02B-019 ) ( NCT00132652 ) Phase IIIb , randomize , open-label , multi-center , 52-week study switch lamivudine telbivudine vs. continue lamivudine treatment adult compensate chronic hepatitis B previously treat lamivudine 3-12 month . CLDT600A2402/NV-02-019 ( NCT00132652 ) hereafter refer study 2402 . PATIENT GROUPS : GROUP A : Patients HBeAg ( + ) HBeAg ( - ) compensate chronic hepatitis B discontinue treatment previous study due efficacy response require treatment meet criteria discontinuation treatment previous study due efficacy , maintain study drug principal investigator . For patient treated telbivudine enrol Group A study 2302 015 , total telbivudine treatment time ( start feeder study baseline end on-treatment period study 2303 ) 208 week . For patient treated lamivudine study 2302/015 enrol group A patient group A study 2401/2402/010 , total telbivudine treatment time 104 week . GROUP B : Patients HBeAg ( + ) HBeAg ( - ) decompensated chronic hepatitis B discontinue treatment previous study due efficacy response require treatment . Patients treat telbivudine study 2301 enrol group B total telbivudine treatment time ( start feeder study baseline end on-treatment period study 2303 ) 208 week . For patient treat lamivudine study 2301 enrol group B , total telbivudine treatment time 104 week . GROUP C : Patients either compensate decompensated chronic hepatitis B , discontinue study drug treatment previous Idenix-sponsored study due efficacy response recommend protocol . Patients eligible treatment discontinuation previous study , principal investigator discretion , continue study therapy , eligible enter study Group C provide treatment discontinue last visit previous study . The feeder study group C current study study 2302/015 , 2401 , 2402 , 010 . For patient enrol group C , total telbivudine treatment time 104 week start baseline feeder study last visit feeder study . Patients enrol current study ( study 2303 ) off-treatment follow-up treatment discontinuation due efficacy . Hence , patient receive study drug except case patient relapse reinitiated treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Patient complete previous qualify IdenixSponsored trial telbivudine Patient discontinue previous IdenixSponsored study Other protocoldefined inclusion criterion may apply Patient pregnant breastfeeding Patient coinfected hepatitis C , hepatitis D HIV Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>